BPG is committed to discovery and dissemination of knowledge
Featured Articles
8/21/2020 3:17:44 AM | Browse: 601 | Download: 1847
Publication Name World Journal of Clinical Oncology
Manuscript ID 54431
Country India
Received
2020-02-17 07:22
Peer-Review Started
2020-02-17 14:14
First Decision by Editorial Office Director
2020-03-28 13:41
Return for Revision
2020-03-28 13:41
Revised
2020-04-09 04:41
Publication Fee Transferred
Second Decision by Editor
2020-07-21 09:03
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director
2020-07-26 21:14
Articles in Press
2020-07-26 21:14
Edit the Manuscript by Language Editor
Typeset the Manuscript
2020-08-13 07:03
Publish the Manuscript Online
2020-08-21 01:38
ISSN 2218-4333 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Study
Article Title Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India
Manuscript Source Unsolicited Manuscript
All Author List Bharat Vaswani, Sagar Bhagat, Saiprasad Patil and Hanmant Barkate
Funding Agency and Grant Number
Corresponding Author Sagar Bhagat, MD, Doctor, Doctor, Medical Services, Glenmark Pharmaceuticals limited, B D Sawant road, Andheri East, Mumbai, Maharashtra 400099, India. sagar.bhagat@glenmarkpharma.com
Key Words Chemotherapy induced nausea vomiting; Netupitant; Palonosetron; Cancer; Chemotherapy;
Core Tip A fixed-dose combination of Netupitant (300 mg) and Palonosetron (0.50 mg) indicated for the prevention of acute and delayed phase of nausea-vomiting in patients on highly and moderately emetogenic chemotherapeutic regimen was recently approved in India. There was no data on the effectiveness of this fixed dose combination in Indian patients in real world setting,the pervious data available was part of regulatory trial conducted in controlled environment, which may not give the real picture of the usage of the molecule in clinical setting. So to look for the effectiveness of the molecule in real world setting this study was conducted among.
Publish Date 2020-08-21 01:38
Citation Vaswani B, Bhagat S, Patil S, Barkate H. Effectiveness of a novel, fixed dose combination of netupitant and palonosetron in prevention of chemotherapy induced nausea and vomiting: A real-life study from India. World J Clin Oncol 2020; 11(8): 606-613
URL https://www.wjgnet.com/2218-4333/full/v11/i8/606.htm
DOI https://dx.doi.org/10.5306/wjco.v11.i8.606
Full Article (PDF) WJCO-11-606.pdf
Full Article (Word) WJCO-11-606.docx